Back-to-back plenary presentations for LAURA and ADRIATIC Phase III trials reinforce the potential of Tagrisso and Imfinzi in early lung cancer settings
Phase I data for tuvusertib, lead asset from the company’s unique portfolio of DDR inhibitors
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
The company has posted net profit of Rs. 405.31 crores for the Financial Year ended March 31, 2024
The company has posted net profit of Rs. 14.23 crores for the Financial Year ended March 31, 2024
The company has posted net profit of Rs.134.43 crores for the Financial Year ended March 31, 2024
The company has posted net profit of Rs.70.76 crores for the Financial Year ended March 31, 2024
The company has posted net profit of Rs. 59.16 crores for the Financial Year ended March 31, 2024
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
Sanofi India has reported total income of Rs. 738.9 crores during the period ended March 31, 2024
Subscribe To Our Newsletter & Stay Updated
